Systematic review finds no ready blood biomarkers for psoriasis biologics, but IL-17A/IL-17F and beta-defensin 2 show promise for precision medicine.
|Articles|September 16, 2021
Supplements and Featured Publications
- Innovative Enhanced Medication Therapy Management Model: MedWise Risk Score, Medication Safety Review, and Health Care Outcomes
- Volume 27
- Issue 16
eAppendix: Association of the MedWise Risk Score With Health Care Outcomes
Advertisement
Supplementary Appendix
Articles in this issue
Advertisement
Related to this article
Geeta Nayyar, MD, MBA, says AI's real health care payoff is cutting administrative friction with clean data and clinical leadership.
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Vitamin K shot refusals rose 77% from 2017 to 2024. Experts break down the drivers, risks, and how clinicians and payers should respond in 5 FAQs.
Oral GLP-1s, Medicare access, and lingering weight bias are reshaping obesity care, says NYU Langone's Holly Lofton, MD.
Activated memory B cells were already enriched at treatment end in the 5 of 21 patients who later cleared HBsAg
Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
Specialty pharmacy leaders will gather in National Harbor for inSPire2026, tackling cell and gene therapy access, AI, and high-cost drug pricing.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
Regorafenib Prescribing in Advanced GIST Deviates From Guidelines
3
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
4
Secondary T-Cell Cancers After CAR T: Rare, Real, and Worth Watching
5